Differentiate non-neovascular CSC from PNV and PCV before choosing PDT or anti-VEGF, and keep unverified cohort figures out of individual risk counselling.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Recognise the shared mechanism and the seven entities
The pachychoroid disease spectrum (PDS) groups related phenotypes. Venous congestion, dilated outer choroidal vessels (pachyvessels), attenuation of the inner choroid and altered permeability are proposed connected mechanisms; compression and retinal pigment epithelium (RPE) dysfunction are models, not one proven causal sequence in every eye. 1 2 4
The listed entities are PPE, CSC, PNV, PCV (aneurysmal type 1 neovascularisation), PPS, pachydrusen and FCE. The spectrum need not be sequential; not every eye progresses and an increased choroidal thickness is common but not a universal defining feature. 1 2
Neovascular age-related macular degeneration (nAMD) and pachychoroid-related neovascular disease can overlap. Choroidal vascular pattern, RPE change and drusen support interpretation, but thickness and absence of soft drusen are not absolute exclusion criteria. Distinguish non-neovascular CSC fluid from active MNV before deciding whether anti-VEGF addresses the cause. 1 2 4
02Link systemic and medication triggers without over-testing
Hormonal and systemic triggers may influence choroidal vascular tone and permeability: increased cortisol, hyperaldosteronism, pregnancy, systemic hypertension, sleep apnoea, chronic stress and H. pylori infection. Medication triggers include steroid application, including nasal or topical routes, and PDE5 inhibitors. 1
These are associations from an unverified teaching source. They do not justify universal H. pylori, sleep or endocrine testing in every patient, and steroid withdrawal is only appropriate when the underlying condition permits. 1
| Category | Original reported associations; not universal testing indications |
|---|---|
| Hormonal / endocrine | Increased cortisol (Cushing, exogenous/endogenous steroids), hyperaldosteronism, pregnancy |
| Systemic | Systemic hypertension, sleep apnoea, chronic stress (type A), H. pylori infection |
| Medication | Steroid application (including nasal/topical), PDE5 inhibitors (e.g. sildenafil) |
03Compare the entities and their imaging signatures
Pachychoroid pigment epitheliopathy (PPE) has RPE change without subretinal fluid (SRF); central serous chorioretinopathy (CSC) can produce SRF. The export uses chronic>6 months and simple/complex FAF changes<2/>2 disc diameters; definitions and linear versus area units need reconciliation, so neither is a universal staging rule. Clinical course and RPE/photoreceptor damage matter alongside duration. 1 4
Pachychoroid neovasculopathy (PNV) is type 1 macular neovascularisation in a pachychoroid context; a known preceding CSC episode is not mandatory. Polypoidal choroidal vasculopathy (PCV) has aneurysmal/polypoidal lesions and may be haemorrhagic; it is not restricted to one ancestry or to thick choroids. Peripapillary pachychoroid syndrome (PPS), pachydrusen and focal choroidal excavation (FCE) are related phenotypes rather than obligatory successive stages. 1 2
The indexed study included 185 eyes of 155 consecutive chronic-CSC patients; vascularised FIPED was reported in 42 eyes (22.7% of all 185), while avascular FIPED occurred in 127 eyes. OCTA was available in 56 eyes. This is not 22.7% of every FIPED or a prospective conversion probability; selected imaging, paired eyes and unreviewed follow-up limit inference. The original 24–39% progression claim still lacks a traced cohort and timeframe. 1 3
| PDS entity | Key imaging findings | Management and limits | Particularities / red flags | Differential diagnosis |
|---|---|---|---|---|
| PPE | RPE alterations, no SRF | Monitoring | Often asymptomatic; precursor status | Early AMD |
| CSC | SRF, pachyvessels | Original 3 month observation shortcut; inspected 2021 statement 4 months; consider PDT individually for persistent disease | Stress and steroid association | VKH syndrome |
| PNV | Type 1 CNV (sub-RPE) | Anti-VEGF | Double-layer sign is not diagnostic alone;22.7% was 42/185 chronic-CSC eyes in one selected study | nAMD |
| PCV | Aneurysmal polyps | Anti-VEGF +/- PDT | ICGA gold standard; haemorrhagic | nAMD |
| FCE | Concave choroidal excavation | Observation | Can be associated with PNV | Staphyloma |
04Use multimodal imaging to separate PDS from AMD
FAF is useful for chronic RPE damage, mottled patterns and descending leakage tracks. EDI-OCT visualises pachyvessels and subfoveal choroidal thickness; typical PED morphologies include the double-layer sign and thumb-shaped PED. OCTA improves detection of vascular networks beneath the RPE when fluorescein leakage masks them. 1
Indocyanine-green angiography (ICGA) is an important reference test for suspected PCV, interpreted alongside OCT and the clinical picture. The double-layer sign describes separation of reflective RPE and Bruch-related lines; FIPED describes a flat irregular RPE detachment. Neither proves neovascularisation alone. Select OCT angiography (OCTA) to investigate a suspected vascular network and recognise segmentation or slow-flow limits rather than prescribing it at one fixed interval. 1 3 4
05Follow the 44-year-old teaching case
2014: visual acuity 6/4.8 both eyes; right eye had a CSC history with current PPE signs, left eye PPE. OCT showed FIPED (double-layer sign) with marked pachyvessels; the patient reported extreme occupational stress. 1
2019: right acuity declined to 6/7.5 with metamorphopsia; active PCV/PNV with thumb-shaped PED and subretinal fluid; new diagnosis of systemic hypertension. The proposed interdisciplinary plan listed blood-pressure monitoring, H. pylori screening, sleep apnoea screening and endocrine exclusion; these remain selective, not universal, actions. 1
06Apply the management algorithm and its limits
The export’s3 month observation shortcut differs from the inspected 2021 German statement: observe acute CSC for the first 4 months unless CNV is present, and consider treatment when SRF persists>4 months without clear regression. Half-dose verteporfin PDT reduces drug dose, whereas half-fluence reduces light energy; they are distinct protocols with potential retinal/choroidal harms. Verify current guidance, local availability and consent rather than treating one duration as automatic. 1 4
The inspected statement recommends anti-VEGF for secondary CNV, and against it for CSC without CNV. Active PNV/PCV require an activity-based plan; selected PCV may receive combined PDT, but neither combination nor treatment of a quiescent network is automatic. New distortion, bleeding or a suspicious PED warrants reassessment; adjust monitoring to findings instead of a universal 6 month minimum. Coordinate any steroid reduction with its prescriber; do not abruptly stop medically required therapy. 1 4
The source's 'DOG/S3' summary and its 6-month minimum follow-up statement are not verified against an exact guideline document here. Half-dose and half-fluence PDT are distinct options and should not be conflated. Anti-VEGF monotherapy is not assumed to fail in all PDS eyes; the concern is poorer response when choroidal hyperpermeability is not addressed. 1 2
What are the main learning points of the pachychoroid spectrum lecture?
Seven entities share choroidal vascular dysregulation; differentiate non-neovascular CSC from PNV and PCV before treatment, and keep unverified cohort figures out of individual risk counselling.
Which findings require urgent reassessment?
New metamorphopsia, sudden visual loss or persistent subretinal fluid beyond several months.
References and access status
- 1Immutable original export; pachychoroid spectrum export
Complete export read; original attribution, recording/transcript and speaker claims not independently verified.
- 2Review 201 choroidal disease (partial historical reuse)
Only partial scope reused; not an exact equivalent. Fresh full-source verification pending.
- 3Guo et al. FIPED in chronic CSC; PMID32251241
Selected indexed abstract methods/results inspected 18November 2026; direct PubMed open returned footer only. Full report, figures and temporal outcomes unread.
- 4DOG/BVA/RG CSC statement, PDF18October 2021
Selected extracted PDF pp 2–4 and 16–17 read 18November 2026; not complete 43 pages or cited trials. Landing page calls it December 2021; PDF says 18October 2021.
For patients
The pachychoroid spectrum groups retinal conditions that share choroidal vascular dysregulation; many findings are monitored rather than treated immediately.
Examination and multimodal imaging guide individual management; this educational text cannot replace your own assessment.
New metamorphopsia, sudden visual loss or persistent fluid needs prompt retinal examination.
New metamorphopsia, sudden visual loss or persistent subretinal fluid beyond several months needs prompt retinal reassessment.